Vyne Therapeutics Ownership
| VYNE Stock | USD 2.89 0.06 2.03% |
Shares in Circulation | First Issued 2016-12-31 | Previous Quarter 42.6 M | Current Value 42.6 M | Avarage Shares Outstanding 5.5 M | Quarterly Volatility 12.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Vyne |
Vyne Stock Ownership Analysis
About 56.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.7. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vyne Therapeutics had not issued any dividends in recent years. The entity had 1:18 split on the 13th of February 2023. VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Vyne Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more information please call David Domzalski at 800 775 7936 or visit https://www.vynetherapeutics.com.Besides selling stocks to institutional investors, Vyne Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Vyne Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Vyne Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Vyne Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Vyne Therapeutics Insider Trades History
About 8.0% of Vyne Therapeutics are currently held by insiders. Unlike Vyne Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Vyne Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Vyne Therapeutics' insider trades
Vyne Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vyne Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vyne Therapeutics backward and forwards among themselves. Vyne Therapeutics' institutional investor refers to the entity that pools money to purchase Vyne Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adar1 Capital Management Llc | 2024-09-30 | 152.9 K | Geode Capital Management, Llc | 2024-09-30 | 134.6 K | Renaissance Technologies Corp | 2024-09-30 | 86.6 K | Springbok Capital Management, Llc | 2024-09-30 | 65.1 K | Blackrock Inc | 2024-06-30 | 60.6 K | Susquehanna International Group, Llp | 2024-06-30 | 60.3 K | Northern Trust Corp | 2024-09-30 | 37.3 K | Ubs Group Ag | 2024-06-30 | 25.1 K | State Street Corp | 2024-06-30 | 15.8 K | Eventide Asset Management, Llc | 2024-09-30 | 1.4 M | Cormorant Asset Management, Llc | 2024-09-30 | 1.4 M |
Vyne Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vyne Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vyne Therapeutics Outstanding Bonds
Vyne Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vyne Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vyne bonds can be classified according to their maturity, which is the date when Vyne Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US92943GAA94 Corp BondUS92943GAA94 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| WRKCO INC 465 Corp BondUS92940PAB04 | View | |
| US92940PAE43 Corp BondUS92940PAE43 | View | |
| WRKCO INC Corp BondUS92940PAD69 | View | |
| US92940PAG90 Corp BondUS92940PAG90 | View |
Vyne Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 12th of November 2024 Other Reports | ViewVerify | |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.72 | Revenue Per Share 0.016 | Quarterly Revenue Growth 0.467 | Return On Assets (0.35) | Return On Equity (0.60) |
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.